iShares NASDAQ US Biotechnology UCITS ETF (DE:OM3E) Price & Chart
DE:OM3E ETF Chart & Stats
- Day’s Range
- EUR 8.88 - EUR 8.89
- 52-Week Range
- EUR 6.43 - EUR 9.17
- Previous Close
- EUR 8.86
- Volume
- 0
- Average Volume (3M)
- 292
- AUM
- 77.81M
- NAV
- 9.97
- Expense Ratio
- 0.37%
- Holdings Count
- 247
- Beta
- 0.45
- Inception Date
- Mar 06, 2018
- Last Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
- Shares Outstanding
- 7,979,440
- Standard Deviation
- N/A
ETF Overview
iShares NASDAQ US Biotechnology UCITS ETF
The iShares NASDAQ US Biotechnology UCITS ETF, trading under the ticker DE:OM3E, is a powerful investment vehicle designed to capture the dynamic growth and innovation within the biotechnology sector of the healthcare industry. This exchange-traded fund (ETF) offers investors a targeted exposure to the cutting-edge advancements and potential breakthroughs in biotechnology, an area renowned for its rapid development and transformative impact on medical sciences and health solutions. As a sector-focused ETF, DE:OM3E strategically invests in a diversified portfolio of biotechnology companies listed on the NASDAQ. These firms are at the forefront of developing novel therapies, pioneering genetic research, and revolutionizing patient care through groundbreaking biotechnological applications. By concentrating on this niche segment, the fund provides investors with a unique opportunity to participate in the potential upside of emerging biotech innovations, which are often characterized by high growth prospects and significant market disruptions. The iShares NASDAQ US Biotechnology UCITS ETF is particularly appealing for those looking to diversify their investment portfolios with a thematic focus on the future of healthcare. It is tailored for investors who are keen on harnessing the potential of biopharmaceutical advancements, personalized medicine, and the burgeoning field of genomic research. With its specialized investment approach, DE:OM3E stands out as a compelling option for those aiming to invest in the next wave of healthcare evolution, while benefiting from the liquidity and flexibility inherent to ETFs.
DE:OM3E ETF FAQ
What was DE:OM3E’s price range in the past 12 months?
What is the AUM of DE:OM3E?
Is DE:OM3E overvalued?
How many shares outstanding does DE:OM3E have?
DE:OM3E ETF Smart Score
Top 10 Holdings
| Name | Weight % |
|---|---|
| GILDGilead Sciences | 8.65% |
| AMGNAmgen Inc | 8.15% |
| VRTXVertex Pharmaceuticals Inc. | 7.61% |
| MRNAModerna | 6.12% |
| REGNRegeneron Pharmaceuticals | 5.35% |
| ILMNIllumina | 2.68% |
| RVMDRevolution Medicines, Inc. | 2.64% |
| BIIBBiogen Inc. | 2.33% |
| ALNYAlnylam Pharmaceuticals | 2.11% |
| RPRXRoyalty Pharma PLC | 1.81% |
| Total | 47.46% |